Brief: Diamyd Medical Provides Update On Diabetes Vaccine Diamyd

Diamyd Medical AB

01/09/2020 07:38

Sept 1 (Reuters) - Diamyd Medical AB  DMYDb.ST :
    * ANALYSES OF PREVENTION TRIALS AND INTRALYMPHATIC PILOT
TRIAL
WITH THE DIABETES VACCINE DIAMYD ®  SUPPORT A POSITIVE TREND IN
GENETICALLY DEFINED SUBGROUPS OF TYPE 1 DIABETES
    * EFFECT ESTIMATE SUPPORTS POSITIVE EFFECT OF SUBCUTANEOUS
INJECTIONS OF DIAMYD ON DELAYING PROGRESSION TO TYPE 1 DIABETES
IN INDIVIDUALS POSITIVE FOR HLA-TYPE DR3-DQ2
    * EFFECT ESTIMATE SUPPORTS NO BENEFIT COMPARED TO PLACEBO IS
SEEN
IN INDIVIDUALS NEGATIVE FOR HLA-TYPE DR3-DQ2

Source text for Eikon:  ID:nWkr75GHNv 
Further company coverage:  DMYDb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))